Table 1 Correlation between CAVT and risk factors
From: Proceedings of Réanimation 2018, the French Intensive Care Society International Congress
Total (n = 76) | CAVT + (n = 12) | CAVT—(n = 64) | p | |
|---|---|---|---|---|
Age (days) | 14 (0–540) | 15(0–120) | 14.15 (0–540) | |
Gender | ||||
Male | 47 (61.84%) | 7 (58.3%) | 40 (62.5%) | NS |
Female | 29 (38.16%) | 5 (41.67%) | 24 (31.57%) | |
Occurrence of an infection | 51 (67.10%) | 12 (100%) | 39 (60.93%) | 0.006 |
Germs KP ESBL | 24 (31.57%) | 6 (50%) | 18 (28.12%) | NS |
Candida spp | 20 (26.31%) | 12 (100%) | 8 (12.5%) | |
Insertion site Internal jugular vein | 72 (94.73%) | 12 (100%) | 60 (93.75%) | NS |
Others | 4 (5.27%) | 0 | 4 (6.25%) | |
CVC size 2.7 | 33 (43.42%) | 6 (50%) | 27 (42.18%) | NS |
4.2 | 42 (55.26%) | 6 (50%) | 36 (56.25%) | |
Reason for admission | NS | |||
Esophagus atresia | 32 (42.10%) | 4 (33.3%) | 28 (43.75%) | |
Small intestine atresia | 17 (22.36%) | 2 (16.7%) | 15 (23.43%) | |
Others | 13 (17.10%) | 6 (50%) | 7 (10.93%) | |
Indication of CVC insertion | NS | |||
Parenteral nutrition | 47 (61.84%) | 7 (58.30%) | 40 (62.5%) | |
Vasopressive drugs | 45 (59.21%) | 9 (75%) | 36 (56.25%) | |
Transfusion | 13 (17.10%) | 4 (33.30%) | 9 (14.06%) |